Background Image
Table of Contents Table of Contents
Previous Page  598 / 1498 Next Page
Information
Show Menu
Previous Page 598 / 1498 Next Page
Page Background

Can cytotoxic chemotherapy be avoided

?

The "RELEVANCE" Trial (Rituximab and Lenalidomide Versus Any

Chemotherapy)

• Phase 3 randomized Study to Compare the Efficacy and Safety of

Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus

Chemotherapy Followed by Rituximab in Untreated Follicular Lymphoma.

• Comparator R-CHOP, R-CVP, R-Bendamustine.

• 7 to 8 weeks later responding patients will continue with 375 mg/m2

rituximab every 8 weeks for 12 cycles.